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The  p53 gene is central to the cellular response to genotoxic
damage (Kastan et al, 1991) and chemotherapeutic agents (Linke
et al, 1996). A coordinated downstream response from p53
involves activation of a number of target genes containing p53-
binding sites, such as mdm-2 and p21/WAF1 (Bueso-Ramos et al,
1996; Steele et al, 1998; Jones et al, 1999). 
Mutation or overexpression of p53 protein has been observed in
up to 52% of primary breast cancers (Ziyaie et al, 2000). Unlike
most other epithelial malignancies, in breast cancer abnormalities
in p53 protein function rather than specific p53 mutations are more
common (Andersen and Borresen, 1995; Ziyaie et al, 2000). p53
status is an important determinant of tumour response to anti-
neoplastic agents (Lowe et al, 1994), with specific mutations of
p53 associated with poor response to systemic therapy (Elledge
et al, 1995; Aas et al, 1996). 
Absolute levels of p53 can be identified using the monoclonal
antibody DO12, which recognises a cryptic epitope in the core
domain of p53 (Vojtesek et al, 1995). DO1, an anti-p53 antibody,
recognises amino acids 20–26 at the n terminus of p53 and is
commonly used for immunohistochemical staining for p53
(Stephen et al, 1995). 
As a consequence of p53 activation there is increased expres-
sion of effector genes including mdm2, p21/WAF1 and p27. Whilst
the mdm-2 protein controls the biological activity of p53 and
targets it for destruction (Haupt et al, 1997), both p21/WAF1 and
p27 act as cyclin-dependent kinase (cdk) inhibitors, preventing
phosphorylation of Rb and release of E2F thus interfering with
S-phase signalling (Sherr and Roberts, 1999). High expression of
p21/WAF1 may be related to short relapse-free survival in breast
cancer (Barbareschi et al, 1996) although the evidence is
conflicting (Elledge and Albred, 1998), and p21/WAF1 mutations
are not common in cancers (Shiohara et al, 1997). p27 is rarely
mutated in human primary breast carcinomas and breast cancer
cell lines (Sgambato et al, 1997); however high levels have been
found in many cell lines even during exponential growth phase,
despite its known role as an inhibitor of cell cycle progression
(Sgambato et al, 1997). 
If it were possible to examine the p53 pathway in vivo in
patients, and thus predict the individual tumour response to
chemotherapy, patients likely to respond to chemotherapy could
proceed with subsequent courses of treatment while others were
spared further, ineffective, treatment and directed to alternative
therapy. Fine needle aspiration (FNA) is used as a routine diag-
nostic investigation, furthermore FNA samples obtain representa-
tive tumour cell populations from a breast cancer (Brotherick et al,
1995) causing minimal tumour disruption and are both acceptable
to patients and yield good material for study. FNAs have been
found to be a viable alternative to intraoperative conventional
surgical biopsy for biochemical analysis of prognostic factors
(Kuner et al, 2000). Cancer cells extracted by FNA have been used
for cytology (Pelosi et al, 1994), polymerase chain reaction
(Gudlaugsdottir et al, 2000), DNA sequencing analysis (Lavarino
et al, 1998), fluorescence in situ hybridisation analysis (Rao et al,
1998) and flow cytometry (Makris et al, 1997). In addition, FNA
reliably allows immunocytochemical determination of biological
variables in primary breast carcinoma (Nizzoli et al, 2000). The
functional significance of key genes in a given cancer may be most
accurately determined by detecting the protein. The aims of this
study were to assess the feasibility of using fine needle aspiration
to examine protein expression of genes from the p53 pathway in
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breast cancer in vivo at multiple time points and to confirm that the
cancer tissue (rather than the normal tissues) accounted for the
proteins detected by Western blotting. 
MATERIALS AND METHODS 
Fine needle aspiration and human tissue 
Fine needle aspirates (FNA) were obtained by a single operator
with a 21G needle and 10 ml syringe, passing the needle through
the cancer 10 times with application of 1–2 ml suction (Hartley
et al, 1988). 500 µ l of chilled phosphate-buffered saline (PBS) was
then drawn up, the needle contents expelled into a chilled eppen-
dorf on ice then spun at 5000 g (4˚C) for 5 minutes. The super-
natant was aspirated and the pellets snap frozen in liquid nitrogen
stored at –70˚C. 
FNAs were obtained from 16 consenting patients prior to
mastectomy or wide local excision for primary untreated breast
cancer and immediately post-operatively from the resected spec-
imen adjacent to blocks used for histological assessment. Post-
operative samples were collected no later than 15 minutes
following excision. Within 15 minutes of excision, 3 mm2 tumour
biopsies were also excised and snap frozen in liquid nitrogen, then
stored with the corresponding aspirates at –70˚C. Local Ethical
Committee approval was obtained. 
Protein extraction and analysis 
Protein was extracted using urea lysis buffer (8.7 ml urea (8 M),
1 ml dithiothreitol (1 M), 50 µ l Triton (10%), 50 µ l NaCl (5 M),
200 µ l Hepes (1 M, pH 7.6). Tumour aspirate pellets, Hela cell
pellets (as a positive control for p53, p21 and p27) and snap frozen
tumour were homogenised in three times the volume of urea lysis
buffer. Samples were left on ice for 15 minutes then spun at 13 000 g
(0˚C) for 10 minutes. The supernatant was transferred into pre-
chilled eppendorfs, snap frozen and stored at –70˚C. Protein
concentration was determined at 595 λ (Bradford, 1976). Bradford
assay showed a 3-fold dilution of protein when the barrel of the
syringe was washed through with PBS for the second time. To
maximise yield, both washes were combined before being spun
down. 
The protein extracted from the FNAs and tumour tissue was
used to perform repeat gels and Western blots of the samples for
confirmation of expression profile comparing pre-operative FNA
vs. post-operative FNA vs. pathology block in all 16 patients. 
SDS/PAGE gel electrophoresis 
SDS/PAGE was carried out using both 10% and 15% polyacryl-
amide resolving gels and standard Laemlli buffer. The 16 tumour
lysates were run on a 10% polyacrylamide gel, before being
probed with the appropriate antibody. Arn8 Lysates with χ radia-
tion and DRB were used as the positive control (Blaydes et al,
2000). 
Antibodies 
Anti-p53 antibodies DO-1 (p53 n-terminus specific) and DO-12
(for absolute levels of p53) supplied by Moravian Biotechnology,
Czech Republic, have been described previously (Blaydes and
Hupp, 1998; Blaydes et al, 2000). p21 WAF1 (Ab1) was supplied
by Oncogene Research Products, Calbiochem and p27 (C-19) anti-
body from Santacruz Biochemistry. Immunoblotting was carried
out using standard methodology. Blots were examined and inter-
preted independently by 3 of the authors (TRH, AMT, HMB); and
there was unanimity for each antibody for all samples. 
Immunohistochemistry 
Immunohistochemistry was performed on 10 neutral-buffered
formalin-fixed, paraffin-embedded sections taken from tissue
adjacent to that used for Western blotting. Sections were
microwaved for 15 minutes in citric acid (0.1 M, pH 6.0) for
antigen retrieval and probed with monoclonal antibodies DO1,
WAF1 or p27. A horseradish peroxidase (HRP) detection system
using diaminobenzidine (DAB) substrate and cells were counter-
stained with haematoxylin. Coverslips were mounted using
organic mountant (DPX). Slides were examined independently by
two of the authors (CP, NK) blinded to the Western blotting data.
There was unanimity in the scoring. Immunohistochemical data
were cross-tabulated with the Western blotting results. 
RESULTS 
Protein was extracted successfully from all FNA and cancer
samples. Fine needle aspiration yielded up to 350 µ g of protein for
Western blots. 
There was no difference in p53 expression between FNA
samples taken pre-operatively and post-operatively on Western
blotting (Figure 1; tumour samples 13a and 13b). However, an
additional (third) band was observed in the homogenised cancer
specimen 13c not seen in 13a or 13b (the FNAs) for one cancer.
Matched venous lymphocyte protein from the same patient did not
demonstrate any p53 expression with DO12 antibody. For DO1,
p21/WAF1 and p27 expression was consistent for the FNAs and
tumour sample both in terms of level of expression and species
detected. 
Individual cancers showed different p53 levels when probed
with DO12 (Figure 2A), with absolute levels of p53 (DO12) in
12/16 patients and p53 expression using an antibody for the N-
terminus (DO1) identified in 10/16 patients. 8 of the 16 tumours
had detectable p21 (Figure 2B), but only 2 cancers had detectable
p27 (Figure 2C). In 2 patients no DO12, DO1, p21/WAF1 or p27
was detected on Western blotting despite positive controls. 
Repeat gels, Western blots and probing demonstrated consistent
expression/absence of expression for each sample and every
protein species. 
Immunohistochemistry 
Sections of the 16 tumours stained by immunohistochemistry
(IHC) confirmed cancer cells were responsible for the positive
bands on Western blotting. In every case IHC-staining intensity
correlated with the Western blotting data (Figure 3). 
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Figure 1 Western blot of patient 13 and positive control (Hela cells) from
(A) preoperative FNA, (B) post-operative FNA and (C) excised tumour,
demonstrating principal p53 species (arrowed) and additional, smaller
species in the FNA and excised tumour samples 1104 HM-L Ball et al 
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DISCUSSION 
FNA is clinically useful in the diagnosis of primary breast cancer
and for the diagnosis and management of metastatic disease. 
This study demonstrates that FNA can be used to assess protein
expression in the p53 pathway using Western blotting. The tech-
nique thus provides a means to perform serial sampling over time
in vivo and could be used to identify and monitor early tumour
response (or failure to respond) at the biochemical level before
clinical responses are evident during neo-adjuvant chemotherapy. 
No difference was observed in p53, p21 or p27 expression
(either in quality or quantity) between samples taken pre-opera-
tively and post-operatively. This suggests that manipulation and
potential short-term hypoxia during surgery does not affect p53
induction at the protein level, unlike human oesophageal cancer,
where there is a marked effect on p53 induction by hypoxia
(Hopwood et al, 1997). The additional species seen in the
homogenised tumour (but not in the FNAs), is unlikely to be due to
blood contamination. It could however be due to additional p53
species in the normal tissue given the greater proportion of cancer
cells in an FNA than in a biopsy (Taxin et al, 1997), or due to early
p53 protein degradation. In clinical practice, blood staining of
FNAs is not uncommon; our data suggest that blood-stained FNA
material is still suitable for p53 protein studies, although absolute
protein concentration may not reflect that of the cancer cell popu-
lation alone. 
As expected, individual cancers showed different p53 levels
within the panel probed with DO12 (Figure 2A) and with DO1
(data not shown) as we have previously described (Craig et al,
1999). This highlights the individuality of the cancers and their
potentially different responses to treatment. DO1 recognises a site
at the n-terminus of p53, which may be cleaved in some tumours,
thus explaining why some samples were DO1 negative, but DO12
positive on Western blotting. Although DO1 is commonly used in
histopathology to detect p53, DO12 is not amenable to IHC tech-
niques. This emphasises the importance of using different anti-
bodies (and techniques) when trying to unravel the p53 pathway in
human breast cancer. 
To further investigate the individuality of the p53 pathway in
each tumour, the expression of p21/WAF1 and p27 (downstream
targets of p53) was also examined by Western blotting and
immunohistochemistry in the same set of tumours. These data
confirm the complexity of the p53 pathway in breast cancer and
suggest that there is another pathway involved in p21 activation
possibly controlled by IRF-1 (Tanaka et al, 1996), as, unexpect-
edly, some samples were p53 negative, and p21 positive. Future
in vivo studies could also study the mutational status of p53 in
the cancer (Lavarino et al, 1998; Gudlaugsdottir et al, 2000),
perhaps using the yeast functional assay (Flaman et al, 1995)
which could be performed on FNA samples prior to
chemotherapy. 
The immunohistochemistry demonstrates concordance with
detectable DO1, p21 and p27 expression from Western blots and
confirmed that it was cancer cells rather than normal tissue
expressing these proteins. However, the Western blots remain
useful to identify which protein species predominate and could be
used to identify and quantify changes between samples. 
Based on this small series, FNA of breast cancers provides
reproducible data on protein expression of p53, p21 and p27. FNA
has the advantage over core biopsy or surgical biopsy, in that it is
well tolerated by patients and can be performed on multiple occa-
sions. Thus it could be used in vivo in the same patient to monitor
changes in protein expression during treatment and hence predict
and monitor the response to chemotherapy or radiotherapy of
primary cancers or metastases in vivo. 
Figure 2 Western blots of cancers 1 to 8 (equal total protein in each lane)
and positive control (Hela cells) demonstrating expression of (A) p53 using
DO12, (B) p21/WAF1 using Ab1 and (C) p27 using C-19; note levels of
expression vary greatly between individual patients 
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Figure 3 Immunohistochemical staining for cancer number 8 showing 
(A) DO1 P53 staining, and (B) p21/WAF1 staining using Ab1 FNA facilitates p53 studies in breast cancer  1105
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